Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cord Blood Transplantation for Hematologic Malignancies
NCT00003270Phase 2Completed
- Sponsor
- Roswell Park Comprehensive Cancer Center
- Start
- Sep 1997
- Primary completion
- Oct 2017
- Modality
- Hematopoietic Stem Cells
- Countries
- 1
01
Overview
Phase 2, open-label trial of umbilical cord blood in acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic myelogenous leukemia (CML) and 6 more (2 arms), sponsored by Roswell Park Comprehensive Cancer Center. Primary endpoint: Overall Response Rate at 100 days. Started Sep 1997; status: completed.
02
Drugs
umbilical cord blood
03
Conditions
acute lymphoblastic leukemia (ALL)acute myeloid leukemia (AML)chronic myelogenous leukemia (CML)myelodysplastic syndrome (MDS)aplastic anemia
Beyond the preview
Go deeper on NCT00003270.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003270.